Clinical advantages of amisulpride in the treatment of acute schizophrenia

Journal of International Medical Research

Volumn 29, Issue 6, 2001, Pages 451-466

  Burns, T ^a   Bale, R ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Acute exacerbation; Amisulpride; Anti psychotic; Schizophrenia

Indexed keywords

AMISULPRIDE; FLUPENTIXOL; HALOPERIDOL; RISPERIDONE;

ADOLESCENT; ADULT; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

EID: 0035670415     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000102900601     Document Type: Review

References (53)

1. Epidemiology of schizophrenia
2. One month prevalence of mental disorders in the US: Based on five epidemiological catchment area (ECA) sites
3. Positive versus negative schizophrenia: A critical evaluation
4. Treatment of negative symptoms
5. Course types in schizophrenia
6. The natural history of schizophrenia: A five-year follow-up study of outcome and prediction in a representative sample of schizophrenia
7. Follow-up studies of schizophrenia I: Natural history and non-psychopathological predictors of outcome
8. Schizophrenia
9. What are the therapeutic needs in schizophrenia and how are they satisfied by new antipsychotics?
10. One hundred years of schizophrenia: A meta-analysis of the outcome literature
11. Motor and mental aspects of extrapyramidal syndromes
12. Why do schizophrenic patients refuse to take their drugs?
13. Drug refusal in schizophrenia: Causes and prescribing hints
14. Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitudes to medication and insight
15. Subjective response to antipsychotics in schizophrenic patients: Clinical implications and related factors
16. New developments in dopamine and schizophrenia
17. Subcortical dopamine and serotonin turnover during acute and subchronic administration of typical and atypical neuroleptics
18. Amisulpride: From animal pharmacology to therapeutic action
19. Psychopharmacological profile of amisulpride: An antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity
20. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity
21. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia
22. Improvement of acute exacerbations of schizophrenia with amisulpride: A comparison with haloperidol
23. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia
24. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: A dose-ranging study vs. haloperidol
25. 2-like antagonist
26. Treatment of negative symptoms in schizophrenia with amisulpride
27. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride
28. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia
29. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride
30. The Brief Psychiatric Rating Scale
31. Negative versus positive schizophrenia: Definition and validation
32. The positive and negative syndrome scale (PANSS) for schizophrenia
33. The quality of life scale: An instrument for rating the schizophrenic deficit syndrome
34. Rating scales for affective disorders: Their validity and consistency
35. A rating scale for extrapyramidal side effects
36. A rating scale for drug-induced akathisia
37. Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
38. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial
39. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial
40. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
41. Risperidone in the treatment of schizophrenia
42. Quetiapine in patients with schizophrenia
43. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia
44. Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: Three efficacy studies
45. Schizophrenia, a high risk factor for suicide: Clues to risk reduction
46. Amisulpride: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia
47. Practice guideline for the treatment of patients with schizophrenia